Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter open-label study of gadobutrol for supra-aortic vessel MR angiography
2010-023001-36Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2011
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gadobutrol in Supra-aortic artery disease (SAAD) and carotid atheroma (CAS), sponsored by Bayer. Primary endpoints: Primary efficacy endpoints and Safety endpoints. Started Mar 2011; status: completed.
02
Drugs
gadobutrol
03
Conditions
Supra-aortic artery disease (SAAD)carotid atheroma (CAS)
Beyond the preview
Go deeper on 2010-023001-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023001-36.